Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Bacterium or component thereof or substance produced by said...
Patent
1994-06-06
1996-10-08
Scheiner, Toni R.
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Bacterium or component thereof or substance produced by said...
4242391, 424542, 4241301, 4241411, 4241421, 4241501, 4241641, 4241671, A61K 3908, A61K 3938, C07K 1646
Patent
active
055629075
ABSTRACT:
Human-derived or human-compatible antitoxins are administered is an adjunct to therapy with a toxin, such as botulinum toxin or an immunotoxin, or as an adjunct to therapy with a combination of toxins, in order to reduce or prevent endogenous production of antibodies to the toxin(s) or other unwanted side-effects.
REFERENCES:
patent: 4341762 (1982-07-01), Haast
patent: 4689299 (1987-08-01), Inseletal
patent: 5053005 (1991-10-01), Bovodic
patent: 5183462 (1993-02-01), Bovodic
Bach et al (1993) Immunol. Today 14(9):421-424.
Arnon (1993) In "Botolinum and Tetanus Neurotoxeus: Neurotrossnussion and Biomedical Aspects" (Das Gypto, ed.) Plenum Press, N.Y., pp. 477-482, title & publ. pages.
Franz et al (1993) In "Botolinum and Tetanus Neurotoxnus: Neurotrossnussion and Biomedical Aspects" (Das Gupta, ed.) Plenum Press, N.Y., pp. 473-476, title & publ. pages.
Frankovich et al., "Clinical trial of botulism immune globulin for infant botulism" The Western Journal of Medicine (1991) 154(1):103.
"Clinical Use of Botulinum Toxin" Reprinted from: NIH Consens. Dev. Conf. Consens. Statement (Nov. 12-14, 1990), vol. 8, No. 8, pp. 1-20.
Hall et al., "Isolation of an Organism Resembling Clostridium baratiWhich Produces Type F Botulinal Toxin from an Infant with Botulism" J. Clin. Microbiol. (1985) 21(4):654-655.
Hatheway, "Bacteriology and Pathology of Neurotoigenic Clostridia" Botulinum adn Tetanus Neurotoxins: Neurotransmission and Biomedical Aspects, DasGupta, ed., Plenum Press, New York, 1993, pp. 491-502.
Aureli et al., "Two Cases of Type E Infant Botulism Caused by Neurotoxigenic Clostridium butyricum in Italy" J. Infect. Dis. (1986) 154(2):207-211.
Suen et al., "Clostridium argentinense, sp. nov: A Genetically Homogenous Group Composed of All Strains of Clostridium botulinum Toxin Type G and Some Nontoxigenic Strains Previously Identified as Clostridium subterminaleor Clostridium hastiforme" Int. J. System. Bacteriol. (1988) 38(4):375-381.
Van Ermengem, "Ueber einem neuen ana eroben Bacillus und seine Beziehungen zum Botulismus" Z. Hyg. Infektionskrankh. (1897) 26:1-56. An English translation can be found in A New Anaerobic Bacillus and Its Relation to Botulism, Rev. Infect. Dis. (1979) 1(4):701-719.
Koening et al., "Clinical and Laboratory Observations on Type E Botulism in Man" Medicine (1964) 43:517-545.
Beller et al., "Repeated Type E Botulism in an Alaskan Eskimo" N. Engl. J. Med. (1990) 322(12):855.
Schroeder et al., "Botulism from Fermented Trout" T. Norske Laegeforen (1962) 82:1084-1086. An English translation, beyond the title, is currently not available.
Mandell et al., eds., Principles and Practice of Infectious Diseases, 3rd Edition, Churchill Livingstone, New York, (1990) pp. 1845.
Brin et al., "Localized Injections of Botulinum Toxin for the Treatment of Focal Dystonia and Hemifacial Spasm" Adv. Neurol.(1988) 50:599-608.
Jankovic et al., "Clinical Correlates of Response to Botulinum Toxin Injections" Arch. Neurol. (1991) 48:1253-1256.
Scott, "Clostridial Toxins as Therapeutic Agents" Botulinum Neurotoxin and Tetanus Toxin, Simpson, ed., Academic Press, Inc., New York, 1989, pp. 399-412.
Hambleton et al., "Antitoxins and Botulinum Toxin Treatment" Brit. Med. J. (1992) 304:959-960.
"Botulinum Toxin" Lancet (1992) 304:1508-1509.
Lees, "Botulinum toxin: Useful in adult onset focal dystonias" Brit. Med. J. (1992) 305:1169-1170.
Hatheway et al., "Immunogenicity of the Neurotoxins of Clostridium botulinum" Therapy with Botulinum Toxin, Jankovic et al., ed., Marcel Dekker, New York, 1993, pp. 93-107.
Schantz et al., "Properties and Use of Botulinum Toxin and Other Microbial Neurotoxins in Medicine" Microbiol. Rev. (1992) 56(1):80-99.
Scott, "Antitoxin Reduces Botulism Side Effects" Eye (1988) 2:29-32.
Black, et al., "Hypersensitivity Reactions Associated with Botulinal Antitoxin" Am. J. Med. (1980) 69:567-570.
Naik, "If the Product Becomes a Cosmetic, They Can Call It Bain de Botulism" Wall Street Journal (Nov. 6, 1992) p. B1.
Creasy et al., eds., Maternal-Fetal Medicine: Principles and Practice (1989) 2nd Ed., W. B. Saunders Company, Philadelphia, Pennsylvania, 613-655.
Kamei et al., "Establishment of Stable Mouse/Human-Human Hybrid Cell Lines Producing Large Amounts of Anti-Tetanus Human Monoclonal Antibodies with High Neutralizing Activity" Eur. J. of Epidem. (1990) 6(4):386-397.
Leary, "Gains Reported in Transferring Genetic Material to Mice" New Youk Times (Mar. 30, 1993) p. B8.
Mariani et al., "A New Enzymatic Method to Obtain High-Yield F(ab).sub.2 Suitable for Clinical Use from Mouse lgG1" Mol. Immunol. (1991) 28(1/2):69-77.
Mittendorf et al., "RH.sub.0 (D) Immunoglobulin (RhoGAM): How It Came into Being" Obstetrics and Gynecology (1991) 77(2):301-303.
Stites et al., eds., Basic and Clinical Immunology (1991) 7th Ed., Appleton & Lange, Norwalk, Connecticut, pp. 291-292, 731-737.
Strauss et al., "Germ Line Transmission of a Yeast Artificial Chromosome Spanning the Murine .alpha..sub.1 (l) Collagen Locus" Science (1993) 259:1904-1907.
Tovey, "Haemolytic Disease of the Newborn and Its Prevention" Brit. Med. J. (1990) 300:313-316.
Anderson et al., "Botulinum Toxin Treatment of Spasmodic Torticollis" Journal of the Royal Society of Medicine, (1992) 85:524-529.
Gilman et al., eds. The Pharmacologic Basis of Therapeutics (1990) 8th Ed., Pergamon Press, New York. The title page and table of contents are enclosed herewith.
Schwarz et al., "Botulism immune globulin for infant botulism arrives -one year and a gulf war later" The Western Journal of Medicine (1992) 156(2):197.
Frankovich et al., "Clinical trial of botulism immune globulin for infant botulism " The Western Journal of Medicine (1991) 154(1):103.
Berkman et al., "Clinical Uses of Intravenous Immunoglobulins" Ann. Int. Med. (1990) 112:278-292.
McDonel, "Clostridium perfringens Toxins (type A,B,C,D,E)" Pharmacol. Ther. (1986) 10:617-655.
Ochs et al., "Survival of IgG Subclasses Following Administration of Intravenous Gammaglobulin in Patients with Primary Immunodeficiency Diseases" Clinical Use of Intravenous Immunoglobulins, Morell et al., eds., Academic Press, London, 1986, pp. 77-85.
Mankarious et al., "The Half-lives of IgG Subclasses and Specific Antibodies in Patients with Primary Immunodeficiency who are Receiving Intravenously Administered Immunoglobulin" J. Lab. Clin. Med. (1988) 112:634-640.
Smith, "Virulence Factors of Clostridium Perfringens" Rev. Infect. Dis. (1979) 1:254-260.
Lee, "Mode of Action of Cobra Venom and its Purified Toxins" Neuropoisons: Their pathophysiological actions Simpson, ed., Plenum Press, New York, 1971, pp. 21-70.
Greene et al., "Use of Botulinum Toxin type F injections to Treat Torticollis in Patients with Immunity to Botulinum Toxin Type A" Movement Disorders (1993) 8:479-483.
Carruthers et al., "Treatment of Glabellar Frown Lines with C. botulinum -A Exotoxin" J. Dermatol. Surg. Oncol. (1992) 18:17-21.
Lees et al., "Treatment of Cervical Dystonia Hand Spasms and Laryngeal Dystonia with Botulinum Toxin" J. Neurol. (1992) 239:1-4.
Vitetta et al., "Immunotoxins: Magic Bullets or Misguided Missiles?" Immunology Today (1993) 14:252-259.
Biro et al., "In vitroEffects of a Recombinant Toxin Targeted to the Fibroblast Growth Factor Receptor on Rat Vascular Smooth Muscle and Endothelial Cells" Circ. Res. (1992) 71:640-645.
Wawrzynczak et al., "Immunotoxins: the Power and the Glory" Immunology Today (1992) 13:381-383.
Wawrzynczak, "Systemic Immunotoxin Therapy of Cancer: Advances and Prospects" Br. J. Cancer (1991) 64:624-630.
Prior et al., "Barnase Toxin: A New Chimeric Toxin Composed of Pseudomonas Exotoxin A and Barnase" Cell (1991) 65:1017-1023.
Zeng et al., "Radioimmunotherapy for Unresectable Hepatocellular Carcinoma Using I.sup.131 -Hepama-1 mAb: Preliminary Results" J. Cancer Res. Clin. Oncol. (1993) 119:257-259.
Burrows et al., "Eradication of Large Solid Tumors in Mice with an Immunotoxin directed Against Tumor Vasculature" Proc. Natl. Acad. Sci. USA (1993) 90:8996-9000.
Amlot et al., "A Phase I Study of an Anti-CD22-Deglycosylated Ricin A Chain Immunotoxin in the Treatment of B-cell Ly
LandOfFree
Method to prevent side-effects and insensitivity to the therapeu does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method to prevent side-effects and insensitivity to the therapeu, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method to prevent side-effects and insensitivity to the therapeu will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-55448